



Figure 1



10A11

003240-2496960


Figure 2



00210-2156990




# Acid/Base Dissolution of Two Different Batches of Sustained Release Guaifenesin Formulations




095494.042800

# Acid/Base Dissolution of Available Guaifenesin Dosage Forms



# Plasma Concentration of Guaifenesin Following the Administration of 1200 mg of Guaifenesin in Three Different Dosage Formulations to Normal Volunteers



095547426042800

Average Guafenesin Plasma Concentrations Following the Administration of Either an Immediate Release Formulation Every 4 Hours or Three Different Modified Release Formulations to Normal Human Volunteers





FIG. 7

09569542-042200

# Acid/Base Dissolution of Guaifenesin Dosage Forms



- ◆ Formulation I
- Formulation II
- ▲ Formulation III
- \* Formulation IV



Plasma Guaifenesin Concentrations Following the Administration of Either 400 mg of an Immediate Release Formulation Every 4 Hours for 33 Doses or a Single Dose of a 1200 mg Modified Release Formulation Every 12 Hours for 11 Doses  
(Mean, Standard Error)





Fig. 9  
09595429042300

Plasma Guaifenesin Concentrations Following the Administration of Either 3 Doses of a 400 mg Immediate Release Formulation Given 4 Hours Apart or a Single Dose of a 1200 mg Modified Release Formulation (Mean, Standard Error)



Plasma Guaiifenesin Concentrations Following the Administration of Either 600 or 1200 mg of Modified Release Guaiifenesin in the Fasted State or 1200 mg After a High Fat Breakfast

